Ciclesonide eent
Name: Ciclesonide eent
Interactions for Ciclesonide
Inhibitory potential of ciclesonide on CYP isoenzymes not studied; des-ciclesonide (the active metabolite) does not appear to inhibit or induce CYP isoenzymes in vitro.1 3
Specific Drugs
| Drug | Interaction | Comments |
|---|---|---|
| Erythromycin | No pharmacokinetic interaction with orally inhaled ciclesonide1 | |
| Ketoconazole | Increases des-ciclesonide levels with orally inhaled ciclesonide1 | Manufacturer recommends caution if used concomitantly with intranasal ciclesonide1 |
| Salicylic acid | No effect on plasma protein binding of des-ciclesonide1 | |
| Warfarin | No effect on plasma protein binding of des-ciclesonide1 |
Renal Dose Adjustments
Data not available
Other Comments
Administration advice:
-This drug should be administered by intranasal route only.
-Spray: Gently shake prior to use and prime the pump by actuating eight times. If the spray is not used for four consecutive days, it should be gently shaken and reprimed with one spray or until a fine mist appears.
-Metered aerosol: Prior to initial use or if not used for ten consecutive days, the container should be primed by actuating three times.
-The manufacturer product information should be consulted for proper use.
Storage requirements:
-Consult the manufacturer product information.
General:
Spray:
-Do not freeze.
Metered aerosol:
-Do not puncture; do not use or store near heat or open flame.
-Exposure to temperatures above 49C (120F) may cause bursting.
-Do not throw canister into fire or incinerator.
Patient advice:
-Avoid spraying into the eyes or directly onto the nasal septum.
Ciclesonide nasal Pregnancy Warnings
Animal studies have shown that subcutaneous administration produced fetal toxicity. There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from this drug. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. US FDA pregnancy category: C Comments: -Hypoadrenalism may occur in infants born of mothers taking corticosteroids during pregnancy. -These infants should be carefully monitored.
Ciclesonide nasal Breastfeeding Warnings
Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant are unknown.